<i>Letter to the Editor:</i> Possible Drug–Drug Interactions Between Cannabinoids and Candidate COVID-19 Drugs

Land, M Hunter; Thomas, Brian F.; Peters, Erica N.; Bonn‐Miller, Marcel O.

doi:10.1089/can.2020.0054

Cited by 7 publications

(13 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This evidence may be important for more detailed observations in the treatment of these individuals, as SARS-CoV-2 directly affects the myocardium, in addition to causing venous thromboembolism and arterial thrombosis in the neurovascular system (46) . Other important factors highlighted were that the CB present in cannabis can cause an important drug interaction, pointing to the need for adequate investigation regarding its use during a suspicion of contamination by SARS-CoV-2 (36) . In addition, attention to the genetic factor that predisposes to cannabis use disorder is necessary, being listed as a risk of increased hospitalization in cases of COVID-19 (29) .…”

Section: Discussionmentioning

confidence: 99%

“…Letter to the Editor: Possible Drug-Drug Interactions Between Cannabinoids and Candidate COVID-19 Drugs (36) 2020 USA Opinion article Objective: Early identification of possible interactions between cannabinoids and drugs that can be used to treat COVID-19.…”

Section: Highmentioning

confidence: 99%

“…On the other hand, researches (16,(20)(21)(30)(31)(32)(33)(34)(35) addressed the possibility of using exogenous CB, especially CBD and THC, in the prophylaxis and treatment of COVID-19 through the suppression of immune activation, with an anti -inflammatory and reduced expression of ACE2 in coronavirus target tissues. A study (36) highlights the risk of drug interactions of THC and/or CBD with anti-inflammatory drugs used in the treatment of infection caused by SARS-CoV-2.…”

Section: Moderatementioning

confidence: 99%

See 2 more Smart Citations

Implications of Cannabis and Cannabinoid Use in COVID-19: Scoping Review

et al. 2022

View full text Add to dashboard Cite

Objective: to identify and synthesize studies on the effects of cannabis use and its relation with SARS-CoV-2, as well as the therapeutic possibilities of using cannabinoids in the prevention and treatment of COVID-19. Methods: scoping review, in the BVS, PubMed, SCIELO, CINAHL, SCOPUS, Web of Science, MedNar, CAPES and ProQuest databases, with no language restriction and year limitation. Narrative synthesis was performed. Results: cannabis use causes changes in the respiratory and vascular system, it reduces the production of cytokines, which affects the users’ immune system, increasing the susceptibility to infection and progression of COVID-19. However, studies have suggested the use of cannabinoids in the prophylaxis and treatment of COVID-19, due to their anti-inflammatory effect. Conclusions: the use of inhaled cannabis increases the progression and severity of the infection. On the other hand, the benefits of cannabinoids seem promising to modulate the immune system, but it needs further studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Highmentioning

confidence: 99%

Section: Moderatementioning

confidence: 99%

See 1 more Smart Citation

Implications of Cannabis and Cannabinoid Use in COVID-19: Scoping Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…CBD influences the principal enzymes (e.g., CYP450-3A4, -2C19, and UGTs) responsible for biotransformation of a wide range of drugs, thus potentially having impact on their pharmacokinetics and pharmacodynamics ( Brown and Winterstein, 2019 ). The hypothetic drug–drug interactions of THC and CBD with the drugs currently used in therapeutic protocols for COVID-19, mainly antiviral and immunosuppressive drugs, have been analyzed ( Land et al, 2020 ). However, the clinical profiles of frail patients infected by COVID-19 must be considered.…”

mentioning

confidence: 99%

Commentary: Use of Cannabinoids to Treat Acute Respiratory Distress Syndrome and Cytokine Storm Associated With Coronavirus Disease-2019

et al. 2021

View full text Add to dashboard Cite

“…These studies in a small number of patients provide us a positive signal that CBD has a great potential to treat a wide range of clinical conditions, but not without conducting additional well-designed clinical trials to support its use as therapy for mental conditions including SUDs. It is also important to keep in mind that cannabinoids may result in adverse pharmacokinetic/pharmacodynamic drug-drug interactions with other pharmacologic agents used in the treatment of patients with COVID-19 (Land et al 2020 ) or patients with substance use disorders.…”

mentioning

confidence: 99%

Cannabis/Cannabinoids for Treating COVID-19 Associated Neuropsychiatric Complications

Khalsa

Maggirwar

Bunt

2021

J Neuroimmune Pharmacol

View full text Add to dashboard Cite

Graphical abstract COVID-19 epidemic has resulted in devastating mortality and morbidity consisting of socioeconomic and health effects that have included respiratory/pulmonary, cardiovascular, mental health and neurological consequences such as anxiety, depression, and substance use. Several effective vaccines have been developed and extensive efforts are underway to develop therapeutics to treat COVID-19. Cannabis and/or its product-cannabidiol (CBD) are being advertised for the treatment of COVID-19 associated mental/neurological complications and substance use disorders. However, research reviewed shows that there is insufficient data from clinical studies to support the use of cannabis or CBD for the treatment of COVID-19 associated mental health and neurological complications. Additional basic and clinical research is suggested to develop cannabis or cannabidiol for the treatment of mental health problems associated with coronavirus infection and or substance use disorders. In the meantime, it is important that the addiction physician/psychiatrist must caution while prescribing or recommending cannabis or CBD for treating such clinical indications. Research shows that currently there is no clinical evidence to support the use of cannabis or any of its compounds including CBD for treating any of the neuropsychiatric complications of COVID-19. Thus, it is important that the addiction physicians/psychiatrists caution their patients from using cannabis or cannabis products for treating any such complications.

show abstract

Letter to the Editor: Possible Drug–Drug Interactions Between Cannabinoids and Candidate COVID-19 Drugs

Cited by 7 publications

References 6 publications

Implications of Cannabis and Cannabinoid Use in COVID-19: Scoping Review

Implications of Cannabis and Cannabinoid Use in COVID-19: Scoping Review

Commentary: Use of Cannabinoids to Treat Acute Respiratory Distress Syndrome and Cytokine Storm Associated With Coronavirus Disease-2019

Cannabis/Cannabinoids for Treating COVID-19 Associated Neuropsychiatric Complications

Contact Info

Product

Resources

About